Furthermore, the LNCaP prostate cancer cell line demonstrated 50% enhanced proliferation in the presence of VEGF165, an effect that was abolished by a neutralizing antibody to VEGFR2, suggesting that the survival signals from VEGF are mediated specifically via VEGFR2 [71]. Here, VEGFA is linked to prostate carcinoma.